ePoster

All ePoster presentations will be available to view anytime throughout the Meeting in an Online Library

Title:

Conjunctival lymphoma as the initial manifestation of an evolved systemic MALT (mucosa associated lymphoid tissue) lymphoma stage IVb

Poster Details

First Author: R. Wakfie Corieh SPAIN

Co Author(s):    J. San Román Llorens   M. Fernández Gurria   A. Guijarro Alaña   B. García Sandoval   I. Jiménez-Alfaro Morote   N. Alejandre Alba     

Abstract Details

Purpose:

To report a case of conjunctival lymphoma as the first manifestation of a systemic lymphoma.

Setting:

Department of Ophthalmology. Fundaci�n Jim�nez D�az University Hospital. Madrid, Spain.

Methods:

Ophthalmological and systemic examination. Histopathology diagnosis and immunohistochemistry of conjunctival tumor and inguinal lymph node. Positron Emission Tomography (PET-CT). Bone marrow aspiration.

Results:

A 58-year-old man with no relevant history consulted for redness and discomfort in the left eye, the lesion presented a rapid growth during 1 year in which he lost clinical follow-up. Visual acuity of 1.0 in both eyes. Biomicroscopy revealed a well-defined, salmon-colored conjunctival mass in the temporal sector of the left eye with no limitations or pain in any gaze position. The conjunctival biopsy showed a MALT lymphoma. The evaluation by the hematology department revealed a non-Hodgkin B lymphoma of the marginal zone with a large retroperitoneal mass and infiltration of the bone marrow: a stage IVb tumor.

Conclusions:

Conjunctival lymphoma is a rare conjunctival tumor that must be ruled out in the presence of a salmon-pink mass in the conjunctiva without adherence to deep planes. A biopsy of the affected tissue with immunohistochemical studies is essential to confirm the diagnosis and achieve its classification. Immediate referral to oncology-hematology is essential for an adequate extension evaluation, which can reveal a systemic location of the disease, thus allowing its treatment and timely follow-up. Currently the patient has received 6 treatment cycles (Bendamustine-Rituximab) with almost complete reduction of the conjunctival lesion.

Financial Disclosure:

None